

Shinji Kobuchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4643000/publications.pdf>

Version: 2024-02-01

49
papers

450
citations

759233

12
h-index

888059

17
g-index

49
all docs

49
docs citations

49
times ranked

554
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. <i>Pharmaceuticals</i> , 2022, 15, 203.	3.8	0
2	Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 1522-1530.	3.3	3
3	Comparing the pharmacokinetics and organ/tissue distribution of anti-methicillin-resistant <i>Staphylococcus aureus</i> agents using a rat model of sepsis. <i>Xenobiotica</i> , 2022, 52, 583-590.	1.1	1
4	A Physiologically Based Pharmacokinetic-Pharmacodynamic Model for Capecitabine in Colorectal Cancer Rats: Simulation of Antitumor Efficacy at Various Administration Schedules. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 301-315.	1.6	4
5	Comparison of In Vivo Transportability of Anti-Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Agents Into Intracellular and Extracellular Tissue Spaces in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 898-904.	3.3	1
6	Population Pharmacokinetic Model-Based Evaluation of Intact Oxaliplatin in Rats with Acute Kidney Injury. <i>Cancers</i> , 2021, 13, 6382.	3.7	1
7	Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats. <i>Xenobiotica</i> , 2020, 50, 146-153.	1.1	7
8	Pharmacokinetics and lung distribution of macrolide antibiotics in sepsis model rats. <i>Xenobiotica</i> , 2020, 50, 552-558.	1.1	5
9	Effect of intact oxaliplatin in plasma on a cold allodynia after multiple administrations in colorectal cancer model rats. <i>Annals of Palliative Medicine</i> , 2020, 9, 3000-3006.	1.2	3
10	Population Pharmacokinetic Model-Based Evaluation of Circadian Variations in Plasma 5-Fluorouracil Concentrations During Long-Term Infusion in Rats: A Comparison With Oral Anticancer Prodrugs. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2356-2361.	3.3	3
11	A validated LC-MS/MS method for the low-level determination of pemafibrate, a novel SPPARM \pm , in plasma. <i>Bioanalysis</i> , 2020, 12, 683-692.	1.5	0
12	Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy. <i>Pharmaceutics</i> , 2020, 12, 125.	4.5	5
13	Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 869-880.	2.3	7
14	Pharmacokinetics of Macrolide Antibiotics and Transport into the Interstitial Fluid: Comparison among Erythromycin, Clarithromycin, and Azithromycin. <i>Antibiotics</i> , 2020, 9, 199.	3.7	17
15	Assessment of Oxaliplatin-induced Chronic Neuropathy and Anticancer Efficacy Through Pharmacokinetic and Toxicodynamic Evaluation of a Rat Model of Colorectal Cancer. <i>Anticancer Research</i> , 2019, 39, 4207-4213.	1.1	5
16	Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 18202.	3.3	23
17	Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity. <i>Biopharmaceutics and Drug Disposition</i> , 2019, 40, 44-48.	1.9	0
18	Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 155-161.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 112, 152-158.	4.0	23
20	Association between circadian and chemotherapeutic cycle effects on plasma concentration of 5-fluorouracil and the clinical outcome following definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in patients with esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 17, 668-675.	1.8	2
21	Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. <i>International Journal of Medical Sciences</i> , 2018, 15, 937-943.	2.5	21
22	Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 452-458.	4.0	9
23	Dissolving microneedles for enhanced local delivery of capsaicin to rat skin tissue. <i>Journal of Drug Targeting</i> , 2017, 25, 420-424.	4.4	7
24	A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study. <i>Bioanalysis</i> , 2017, 9, 163-171.	1.5	3
25	Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 707-718.	1.6	9
26	Dissolving Microneedles as Skin Allergy Test Device. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 531-534.	1.4	16
27	Therapeutic Drug Monitoring of Vancomycin in Dermal Interstitial Fluid Using Dissolving Microneedles. <i>International Journal of Medical Sciences</i> , 2016, 13, 271-276.	2.5	43
28	Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 517-523.	2.3	2
29	Transport of Azithromycin into Extravascular Space in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6823-6827.	3.2	9
30	Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1027, 227-233.	2.3	8
31	A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. <i>Biomedical Chromatography</i> , 2016, 30, 1549-1555.	1.7	27
32	Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. <i>Xenobiotica</i> , 2016, 46, 597-604.	1.1	10
33	Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats. <i>Xenobiotica</i> , 2015, 45, 19-28.	1.1	8
34	A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1000, 22-28.	2.3	11
35	Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats. <i>Xenobiotica</i> , 2014, 44, 804-818.	1.1	8
36	Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats. <i>Journal of Pharmacological and Toxicological Methods</i> , 2014, 70, 134-144.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Application of Dissolving Microneedles to Glucose Monitoring through Dermal Interstitial Fluid. <i>Biological and Pharmaceutical Bulletin</i> , 2014, 37, 1776-1781.	1.4	19
38	Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2013, 38, 171-181.	1.6	8
39	Effects of oxidative stress on the pharmacokinetics and hepatic metabolism of atazanavir in rats. <i>Free Radical Research</i> , 2013, 47, 291-300.	3.3	7
40	Pharmacokinetic/Pharmacodynamic Modeling of 5-Fluorouracil by Using a Biomarker to Predict Tumor Growth in a Rat Model of Colorectal Cancer. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2056-2067.	3.3	12
41	A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 365-376.	1.9	10
42	Pre-therapeutic Assessment of Plasma Dihydrouracil/Uracil Ratio for Predicting the Pharmacokinetic Parameters of 5-Fluorouracil and Tumor Growth in a Rat Model of Colorectal Cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 907-916.	1.4	13
43	Time-Dependent Interaction of Ritonavir in Chronic Use: The Power Balance Between Inhibition and Induction of P-Glycoprotein and Cytochrome P450 3A. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2044-2055.	3.3	11
44	Effects of Obesity Induced by High-Fat Diet on the Pharmacokinetics of Atazanavir in Rats. <i>Drug Metabolism Letters</i> , 2013, 7, 39-46.	0.8	3
45	Pharmacokinetics and distribution of fluvoxamine to the brain in rats under oxidative stress. <i>Free Radical Research</i> , 2012, 46, 831-841.	3.3	5
46	Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 515-523.	2.4	15
47	Decrease in Brain Distribution of Fluvoxamine in Experimental Hyperlipidemic Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011, 14, 414.	2.1	3
48	Effect of Oxidative Stress on the Pharmacokinetics of Clomipramine in Rats Treated with Ferric-Nitrilotriacetate. <i>Drug Metabolism Letters</i> , 2011, 5, 243-252.	0.8	5
49	Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 635-642.	5.6	19